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ABSTRACT
Objective: Cancer is the deadliest disease affecting the life of the people all around the world. Colon cancer is the cancer which is affecting the colon 
region it is the last part of the gastrointestinal tract which is mainly responsible for the absorption of water and minerals from the food debris. Colon 
cancer is the second most cancer creating death in the world. It affects both male and female equally. Curcumin is a flavonoid used from decades for 
the treatment of various ailments including cancer. This present work is to formulate Self-nanoemulsifying drug delivery (SNEDDS) system with the 
help of curcumin for colon delivery. 
Materials and Methods: Nanoemulsion was prepared using the curcumin pre-concentrated self-nanoemulsifying drug delivery system, with which 
tablets were prepared and coated with pectin followed by the evaluation test such as in vitro dissolution and cell line studies. 
Results: Solubility profile of curcumin was found with a greater impact using Capmul MCM and Labrafac PG which is then added with the surfactants 
and co-surfactants and were converted into Nano-droplets. F1 formulation was selected after carrying out the characterisation studies and converted 
into a tablet dosage form and then coated with pectin, in vitro studies depicted a release of 80% in pH 6.8. 
Conclusions: Formulation of a solid self-Nano emulsifying drug delivery system using curcumin was successfully carried out. From the results 
obtained, the formulation (F1) was selected for the formation of the tablets and the further experimental part is carried out. The tablet dosage form 
is then coated with pectin and used for targeting the colon cancer cells for its treatment.
Keywords: Colon cancer, Curcumin, Pectin, Self-nanoemulsifying drug delivery system.
INTRODUCTION
Colorectal cancer also coined as colon cancer or rectal cancer is the 
development of cancer in the colon or rectal region which is one of 
the leading causes of death in this world. The results of the modern 
lifestyle, lack of exercise, and alcohol consumption lead to an increase 
in the number of colorectal cancer worldwide; hence, there is a need 
for developing a novel and environmentally benign drug therapy 
for the development of colorectal cancer [1]. The use of the herbal 
ingredient to treat and for the prevention of cancer is helpful in 
terms of its biocompatibility, biodegeneration, and non-toxic effect. 
Flavonoids are the compounds which are commonly extracted from 
different parts of the plant which are mostly used for the treatment 
of the colon cancer [2]. The antioxidant content present in them is the 
major reason behind this phenomenon. Curcumin found in turmeric 
has a potent power to self-destruct colon cancer cells [3]. The adverse 
effects caused by the chemotherapeutic drugs such as hair loss, damage 
to the cells in the mouth, digestive tract, and reproductive tract, weight 
changes could be minimized to an extent by introducing curcumin in 
the therapy [4,5]. The easy availability and the safety in administration 
even at a higher dose provide an additional advantage of using 
curcumin in the treatment. Curcumin belongs to the biopharmaceutical 
classification system (BCS) Class II system with a poor solubility 
nature. The solubility issues could be managed using the lipid drug 
formulation approach [6,7]. To increase the solubility of the drug in the 
gastrointestinal tract and also to increase the bioavailability of Class 2 
and Class 4 drugs, lipid-based drug delivery system (LBDDS) has been 
adopted. In LBDDS, the most common approach is the incorporation 
of the drug compound in the lipid vehicles such as oils, and surfactant 
and cosurfactant (SCoS) to form a nanoemulsion (NE). The later 
mixture is typically called self-dispersing system often referred to as 
a self-emulsifying drug delivery system or self-nanoemulsifying drug 
delivery system (SNEDDS) [8-10].
Oral drug delivery system is the most preferred and convenient option 
for cancer treatment. At present, pharmaceutical solid dosage form 
includes tablets, granules, capsules, and spheroids and among those 
tablets account for 70% of all the approved pharmaceutical solid dosage 
forms [11]. The pH range in the gastrointestinal is actively used as a 
targeted mechanism and for the dissolution and the release polymers. In 
our approach, the tablet formulation is coated with the polymer pectin. 
The pH variation throughout the organs in the gastrointestinal tract is 
used for the drug delivery by an enteric coating [12]. To over the above-
explained barriers during the therapy, this formulation was developed 
to provide an effective and efficient therapy for the treatment of colon 
cancer and to provide specificity at the site of action.
MATERIALS AND METHODS
Reagents
Curcumin and pectin were purchased from HiMedia Ltd., India. Capmul 
MCM, Labrasol, Transcutol HP, Kolliphor, Labrafil M, and Labrafac PG 
were obtained as a gift sample from Gattefosse India Pvt. Ltd., Mumbai. 
Castor oil, olive oil, and linseed oil were obtained from Sigma Ltd., India.
Solubility studies
The solubility of the curcumin in various oils (Capmul MCM, oleic acid, 
linseed oil, castor oil, Labrafac PG, olive oil, corn oil, and soybean oil), 
surfactants (Labrasol and Kolliphor), and cosurfactants (Transcutol 
HP and Labrafil M) was performed by the shake flask method. UV 
spectroscopy at a wavelength of 428 nm was used to determine the 
concentration of the drug dissolved [13].
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i7.33231
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Formulation of NE by spontaneous emulsification method
The different ratio of Smix from 1:1 to 1:9 was prepared and individually 
mixed with the different proportions of oil and titrated against the 
water until a translucent to transparent liquid is obtained [14,15].
Evaluation of NE
Particle size distribution, zeta potential, and polydispersity index (PDI)
Particle size distribution, zeta potential, and PDI of the prepared 
formulation of NE were found out using dynamic light scattering 
technique. Malvern Zetasizer Nano Series ZEN1002 (Malvern, UK) was 
the instrument used in a cuvette DTS0012 in the wavelength of 532 nm 
which comprised green laser and had scattering angle of 173°C [16].
Preparation of curcumin pre-concentrated SNEDDS
The oil in which concentration is maximum soluble was used 
similarly to the Smix combination of surfactant:cosurfactants 
(Kolliphor:Labrasol):transcutol, respectively [17,18]. Pre-concentrate 
SNEDDS was prepared, containing a fixed proportion of curcumin dissolved 
in a mixture of vehicles. About 40 mg of curcumin drug was accurately 
weighed and dissolved in oils using a magnetic stirrer until a homogenous 
solution was formed to this SCoSs were added. The resultant pre-concentrate 
solution was vortexed for 10 min and kept in the Orbital Shaker for 24 h. 
This pre-concentrated was used for the preparation of tablets [19-21].
Preparation of curcumin pre-concentrated SNEDDS-loaded tablets
Curcumin containing SNEDDS incorporated tablets were performed by 
the direct compression technique. For preparing curcumin tablets, the 
optimized oil and Smix used for formulating curcumin pre-concentrate 
were used as the vehicle. Six formulations of SNEDDS tablets (T1–T6) 
were prepared with a fixed proportion of curcumin dissolved in a 
mixture of oil liquid and mixed with solid pharmaceutical excipients. 
The solid excipients used were the mixture of Neusilin or Kolliphor or 
anhydrous dextrose, magnesium stearate, and talc.
Coating of curcumin tablet SNEDDS
The fabricated coating pan was used for coating the prepared tablets 
with pectin (1%). The polymeric weight gain was calculated and used 
for the assessment of the morphology of coating. After the coating, 
the tablets were cured in an oven for 2 h at 40°C. Then, the prepared 
polymeric coated tablets were tested for drug release at various pH 
conditions [22].
Characterization of curcumin pre-concentrate powders
Bulk density of pre-concentrate powders
An accurately weighed quantity of mixtures of adsorbed powders 
was poured into the graduated cylinder and the bulk volumes were 
accurately measured before tapping and after tapping, bulk density was 
calculated separately using the formula [23-25].
Bulk density = M/vb
Where,
M = Mass of the spheroids and vb = Bulk volume
Compressibility pre-concentrate powders
Accurately weighed quantities of mixtures of adsorbed powders were 
poured into the graduated cylinder and the bulk volumes were noted 
before and after tapping. Using the tapped density value and the value 
of bulk density, Carr’s index was calculated. The compressibility index 
of the adsorbed powder was evaluated by Carr’s compressibility index 
using the formula.
Carr s index
Tapped density - bulk density
Tapped density
'  100
The angle of repose pre-concentrate powders
The fixed funnel method was used to check the flowability of the 
powder and to determine the angle of repose. The mixtures of the 
powder were poured into the funnel with the help of the apex conical 
pile so that the pile reaches the funnel’s tip. The radius (r) and height 
of the pile (h) were then found out. The angle of repose (θ) for samples 
was determined using the following formula:
Tan-1= (h/r) = angle of repose
Where,
H = Height of heap of powder
R = Radius of the heap of the powder,
Therefore = tan −1 (h/r)
Evaluation of SNEDDS containing tablets
Friability
Roche friabilator tester (Electrolab, Mumbai, India) was the instrument 
used to find out the friability of the tablets. Ten tablets were used for 
testing the impact at 25 rpm for about 4 min. Then, the remaining 
particles were separated by sieving and the tablets on the sieve were 
weighed and the percentage friability was calculated from the difference 
of the tablets before and after friability testing.







Randomly 20 tablets were selected. Then, each tablet was tested for 
hardness using a hardness tester and the value at which the tablet 
breaks off was noted. From these values, the average tablet hardness 
and the variety of hardness were determined based on the standard 
deviation.
Diameter and thickness
Randomly 20 tablets were picked. Then, the diameter, as well as the 
thickness of the tablets, was checked individually using Vernier caliper.
Weight variation
Randomly 20 tablets were selected. Each tablet was weighed 
individually. The weight was noted. The average of the weights was 
calculated. The percentage deviation of the tablets was calculated from 
the average weight of the tablets.
Disintegration time
Six tablets were placed in different tubes of the basket and the basket 
was lifted up and down for 60 min. Here 0.1 N HCl and 6.8 pH buffer 
were used as immersion fluid. The solutions were maintained at 37°C ± 
2°C. The time at which each tablet disintegrates was noted.
In vitro dissolution study
The drug release standard for delayed release formulations (enteric-
coated tablets) was used to determine the in vitro release of the tablets. 
The same method as done by Sarasija and Hota was used by slightly 
modifying the pH medium, which was based on the different transit 
time starting from the stomach to the colon. USP paddle apparatus was 
used to carry out the dissolution studies (USP-XXIII-dilution method). 
Various pH conditions mimicking the in vivo conditions (pH 1.2 for 1 h, 
pH 3.0 for 1 h, and pH 6.8 for up to 3 h) were optimized throughout the 
study period. About 500 ml of 1.2 pH buffer was poured into the basket 
and was pellets which were put into the medium and the paddle was 
rotated at 50 rpm. About 1 ml of samples was withdrawn at determined 
time intervals and then was immediately replaced with the 1.2 pH buffer 
of equal quantity. The temperature of 37°C was maintained inside the 
basket. The amount of drug release was determined using UV-visible 
spectrophotometer at a wavelength of 428 nm [26-30].
Cell line study
The effect of curcumin-loaded spheroid formulation on cell growth 
was found in human colon carcinoma, HT-29 cell line (National 
Centre for Cells studies, Pune). The cell growth inhibitory activity of 
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the samples was performed using 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay. The fractional 
absorbance was calculated by the following formula [30-32]:
% cell survival
Mean absorbance in test wells
mean absorban

ce in control wells
100
Statistical analysis
The results depicted that bellows are expressed as mean ± deviation. 
The difference among the groups was calculated using Student’s t-test. 
p≤0.05 is considered to be statistically significant.
RESULTS AND DISCUSSION
Solubility studies of the drug in different oils
Solubility is considered as an important aspect in the formulation of NE, 
as the drug remains in liquid form solubilized in the oil phase. Therefore, 
the oil in which the drug exhibited maximum solubility was selected 
for the preparation of the formulation. From Table 1, it is evident 
that Capmul MCM:Labrafac PG (1:1) showed maximum solubility of 
curcumin 45.339 mg/mL. Hence, Capmul MCM:Labrafac PG was selected 
for the formulation of NE. The increased solubility of the drug could be 
due to the more affinity toward the respective oil. Curcumin being a 
lipophilic drug which comes under BCS II drug, though lipophilic it is 
not soluble in all the oils. The drug is soluble in Capmul MCM:Labrafac 
PG which is a combination of medium chain triglycerides and macrogol. 
The combined solvent property of both macrogol and triglycerides 
influenced the increased solubility of the drug, as compared with that of 
oils such as Capmul MCM or Labrafac PG used as individually. The report 
clearly depicts the solubility profile in other oils are comparatively low. 
In olive oil, the solubility profile was found to be only 3.8 mg/ml. In 
other oils also, the solubility profile range was between 3 and 10 mg/ml. 
When Capmul MCM and Capmul MCM + Labrafil were used as a solvent, 
the solubility profile was found to be 33.5 mg/ml and 32.61 mg/ml, 
respectively. Hence, the oil which shown the higher solubility range 
which is 45.33 mg/ml was selected for further studies.
Formulation of NE by spontaneous emulsification method
To prevent the coalescence in the prepared NE, the concentration of 
the SCoS used plays a key role in the formation of the barrier at the 
interface. Smix gets adsorbed at the interface, reducing the energy 
required for NE formation, thus improving the thermodynamic stability 
of the NE formulation. In this method, the following observation was 
recorded. The visual observations during aqueous phase titration using 
SCoS 1:1–1:3 are recorded in Table 2.
In Smix ratio 1:1, when SCoSs are in equal ratio, the ratio of oil and 
Smix, i.e., from formulation (F1 to F3) translucent formation of NE 
was observed. In the Smix ratio 1:3, the ratio of oil and SCoS, i.e., from 
formulation (F2 to F3 and F8 to F9) translucent formation of NE was 
observed and a final ratio of SCoS 1:4, the ratio of oil and Smix from 
formulation (F3 to F9) only milky and emulsion gel was observed. 
Therefore, 1:1 ratio of Smix having formulation (F1) was selected 
for further studies. In other formulations, when the aqueous-based 
titration method was used, the results obtained were not the formation 
of the NE, various other records such as the formation of the emulsion, 
emulsion gel, and milky emulsion were found out. When we carried out 
the studies with 1:1 ratio of SCoS mixture from F4 formulation, NE was 
not formed. In the ratios 1:2 and 1:3 the NE is not formulated clearly. 
Hence, we conclude with the decision of using F1 formulation for the 
further studies.
Particle size distribution, zeta potential, and PDI
Particle size increases with an increase in the concentration of oil in 
the formulation and decreases with increase in the concentration of 
Smix. Among the different ratios of Smix (1:1–1:3), the ratio of Smix 
(1:1) having formulation F1 (1:1) was observed to form the NE which 
was found to have a particle size distribution of 68.83 nm with a PDI 
1.000, and zeta potential −2.00 mV with 100% transmission was 
selected for incorporating into tablet formulation. The optimized Smix 
ratio (1:1) having formulation F1 (1:1) was selected based on least 
particle size and PDI. The other parameters such as the percentage 
transmission and conductivity were found to be satisfactory for all the 
formulations. The results are displayed in Table 3. The PDI was also 
low; the zeta potential was found to be −2.00, which shows that the 
Smix (1:1) ratio having formulation F1 (1:1) is stable. These results 
are evidenced in Table 3. Sample 1 has a particle size of 68.83 nm 
which is comparatively low as compared low with that of the samples 
2, 3, and 4, wherein these three samples, the particle size is found to 
be below 200 nm which is the optimal range of nanoparticles but is 
higher than 100 nm, where in sample 1, the particle size is found to 
be below 100 nm.
Formulation and optimization of curcumin SNEDDS tablets
Six formulations of SNEDDS tablets (T1–T6) were prepared by direct 
compression method containing a fixed proportion of curcumin 
Table 2: The visual observations during aqueous phase titration 
using SCoS 1:1–1:3 are recorded
SCoS Oil: SCoS
F1 F2 F3 F4 F5 F6 F7 F8 F9
1:1 1:1 1:2 1:3 1:4 1:5 1:6 1:7 1:8 1:9
NE NE NE E E E EG EG EG
1:2 1:1 1:2 1:3 1:4 1:5 1:6 1:7 1:8 1:9
M NE NE EG E M E NE NE
1:3 1:1 1:2 1:3 1:4 1:5 1:6 1:7 1:8 1:9
E NE NE EG EG E EG E M
NE: Nanoemulsion, E: Emulsion, EG: Emulsion gel, M: Milky
Table 3: Characterization of nanoemulsion
Samples Particle size (nm) PDI Zeta potential
1 68.83 1.00 −2.00
2 121.2 0.263 −3.2
3 143.1 0.250 −3.34
4 185 0.226 −4.71
PDI: Polydispersity index
Table 4: Evaluated parameters of curcumin tablets
Parameters Results (mean±SD)
Bulk density 0.517±0.9 g/ml
Tapped density 0.604±0.15 g/ml
Compressibility index 14.1±0.29%
Hausner’s ratio 1.15±0.69






Table 1: Solubility studies of curcumin using different oils
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(40 mg) and the results are shown in Table 4. In formula 1 (T1), using 
only the Neusilin-375 mg as adsorbents, it was observed that the tablet 
prepared was very fragile and stick on punch, which had an irregular 
shape, defect tablet. This may be due to decreased concentration of 
binder. As a result, in formula 2 (T2), using only the kholidon-523 mg 
as a binder, it was shown that the tablet formed was very fragile and 
brittle, which gave an irregular form; in addition, some powders were 
observed to stick on the upper punch. As a result, in formula 3 (T3), 
using only anhydrous dextrose-1100 mg as the binder, it was shown 
that the tablet formed was fragile and size of the tablet is more 
compared to other formulation. Therefore, the addition of the binder, 
methocel 5% and lubricant 2% (talc and magnesium stearate) (formula 
– T4, T5, and T6), was done. Initially, NEs of the tablets prepared 
without curcumin formed a perfect tablet, but the tablets which were 
loaded with curcumin were stickier on the upper punch and the surface 
of the tablet was not smooth. When compared to the formula T5 with 
T6, the outcome was good instead, although there was still very little 
not perfect smoothness observed on the surface of the tablet. Moreover, 
formula T5 highly stickiness on the punch, which gave a rough tablet 
surface, was obtained. The tablet prepared using the formula T4 has 
perfect hardness, smooth surface and it exhibited no stickiness on the 
punch.
Coating of tablets
The prepared tablets were coated with pectin (1%) using a fabricated 
coating pan and check the morphology of coating to do dissolution in 
different strength of phosphate buffer because being our target was 
colon, it consists of pectinase enzyme which has the ability to digest the 
pectin coating of the tablet that initiates drug release.
Characterization of curcumin tablets
The Micromeritic properties of tablets shown in Table 4, such as 
bulk density, tapped density, Hausner’s ratio, compressibility, and 
angle of repose, are found to be within the limit. And also, friability, 
weight variation, hardness, and thickness also found to be within 
limits. The bulk density and tapped density of the SNEDDS was 
found to be in the range of 0.570 g/ml and 0.604 g/ml. Since the 
low values of compressibility (14.4%) and the angle of repose <30° 
signify good flowability of the SNEDDS, it showed that had smooth 
flow properties ensuring homogenous filling capacity. Friability of 
SNEDDS was found to be <1% w/w, the hardness of SNEDDS was 
found to be 4.21 kg/cm2, the thickness of SNEDDS was found to be 
4.6 mm, and weight variation of SNEDDS was found to be 0.49%. The 
formulation and optimization of curcumin SNEDDS tablets are given 
in Table 5.
Disintegration study
Six tablets of pectin (1%) coated tablets were placed in the 
disintegration test apparatus and the experiment is carried out as per 
procedure and 1% pectin coated tablet did not show disintegration 
in 0.1 HCL. However, in phosphate buffer 6.8, 1% shows the complete 
disintegration at 5.48 min. Because pectin is a pH-dependent polymer, 
it dissolved in alkaline pH; the results are shown in Table 6.
In vitro dissolution study (release profiles)
Coated curcumin tablets showed a complete release within 3 h. The 
tablets were found to stay intact up to pH 3.0, disintegrated at pH 
6.8, and the release was observed for around 2 h. Greater than 80% 
of drug release was observed at pH 6.8. Batches prepared using pectin 
Table 6: Disintegration study of the tablets
Formulation 0.1 HCL (2 h) Phosphate buffer 6.8 (1 h)
Pectin 1% - 5.48 min
Table 7: Cumulative percentage release of curcumin-coated 
tablets









Table 8: Cell line studies
S.No. Weight of 
spheroids (mg)
Percentage of cell viability
Formulation Free curcumin
1 1.56 68 70
2 3.125 51 62
3 6.25 45 55
4 12.5 30 48
5 25 25 35
6 50 22 30
7 100 21 28
Table 5: Formulation and optimization of curcumin self-nanoemulsifying drug delivery system tablets
Formula T1 T2 T3 T4 T5 T6
Neusilin 375 mg 375 mg
Kholidon 523 mg 523 mg
Anhydrous dextrose 1100 mg
Methocel 5% 5% 5%
Magnesium stearate 1% 1% 1%
Lubricant 1% 1% 1%
Interference Sticking Sticking Sticking 
and picking
Smooth surface Stick on punch surface not 
smooth
Stick on punch surface not 
smooth
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1% showed a minimum release of 0.33% ± 0.5% at pH 3 and maximum 
release of 88.91% ± 0.85% at pH 6.8 (Table 6), and this batch was 
selected as an ideal and used for the further studies. The cumulative 
percentage release of curcumin-coated tablets is reported in Table 7.
Cell line study
The viability of cells was measured using the MTT test to evaluate the 
cytotoxicity of curcumin on HT29 cell lines. Results of cell viability 
assay are shown in Table 8. The IC50 value of the formulation was found 
to be 21.1 µg/mL while that of free curcumin had 36 µg/mL. Compared 
to treated cells, no cytotoxicity was observed in the cells exposed to 
the blank formulation. The insignificant change was observed after 
performing the test in a similar manner up to 72 h.
CONCLUSIONS
The tablet formulation containing curcumin-loaded SNEDDS was 
prepared and evaluated. From the results obtained, the formulation 
(F1) were selected for the formation of the tablets and the further 
experimental part is carried out. The micromeritic properties of 
tablets, such as bulk density, tapped density angle of repose, and 
compressibility, were found to be within the limit.
Therefore, curcumin loaded/entrapped in SNEDDS and formulated to 
spheroids can be used successfully in the treatment of colorectal cancer 
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